Table 4 Kaplan–Meier survival estimates for in vivo effectiveness of AS-AQ versus AL (PP without and with PCR correction)
Effectiveness evaluation | AS-AQ (95% CI) | AL (95% CI) | P-value* |
|---|---|---|---|
n = 114 | n = 128 | ||
PP without PCR correction | |||
ACPR day 28 | 94 | 107 | 0.363 |
Censored (Persistent vomiting of study drug, LTFU, WT and PV) | 16 | 13 | |
Treatment failures | 4 | 8 | |
Cumulative incidence of success, day 28 | 96.5% (93.2–99.8) | 93.8% (89.1–98.5) | |
PP with PCR correction | 0.605 | ||
ACPR day 28 | 94 | 107 | |
Censored (Persistent vomiting of study drug, LTFU, WT,PV and re-infections) | 17 | 16 | |
Treatment failure (recrudescence) | 3 | 5 | |
Cumulative success rate, day 28 | 97.4% (94.1–100.0) | 96.1% (92.4–99.8) | |